Dataset Information

Oct-4: a prognostic biomarker of urinary bladder cancer in North India.

ABSTRACT: Background:The objective of this study was to evaluate Octamer-binding transcription factor 4 (Oct-4), neutrophil to lymphocyte ratio (NLR) and body mass index (BMI) as independent prognostic biomarkers for prediction of urinary bladder cancer (UBC) outcomes. With the advancement in prognostic biomarker discovery, tumor recurrence is difficult to accurately predict in UBC. UBC is costly to treat due to the requirement of frequent invasive follow-up sessions. Therefore, it is of utmost importance to evaluate good prognostic biomarkers for UBC surveillance. Methods:We studied 39 UBC tissue samples. Oct-4 protein expression was evaluated semiquantitatively by immunohistochemistry (IHC). Complete blood count data and body weight as well as the height of the patients were retrieved and recorded before the date of the first transurethral resection of bladder tumor (TURBT). The follow-up period was 48?months for recurrence-free survival (RFS), progression-free survival (PFS), and overall survival (OS). Results:Oct-4 expression profile was found to be significantly associated with gender (p?=?0.028), tumor grade (p?=?0.038), tumor stage (p?=?0.003), lymph node status (p?=?0.029), recurrence (p?=?0.004), progression (p?=?0.011), and treatment modality (p?=?0.016). Tumor grade and progression were found significant with NLR values (tumor grade, p?=?0.006; progression, p?=?0.038) and BMI (tumor grade, p?=?0.036; progression, p?=?0.014). Moreover, BMI was also significantly associated with UBC recurrence (p?=?0.014). Kaplan-Meier survival analysis showed poor prognosis with both high Oct-4 expression (RFS, p?=?0.001; PFS, p?=?0.004; OS, p?=?0.014) and high NLR values (RFS, p?=?0.049; PFS, p?=?0.004; OS, p?=?0.005). Patients with high BMI too had poor RFS (p?=?0.025) and poor PFS (p?=?0.032). Furthermore, multivariate Cox regression analysis, indicated Oct-4 as an independent prognostic biomarker for RFS (HR?=?0.240, 95% CI, 0.072-0.804, p?=?0.021). Conclusions:We conclude that the expression profile of Oct-4 will be beneficial in prediction of UBC recurrence, and could have profound implications on the development of new therapeutic targets for UBC treatment.

SUBMITTER: Siddiqui Z

PROVIDER: S-EPMC6769204 | biostudies-literature | 2019 Jan-Dec

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Oct-4: a prognostic biomarker of urinary bladder cancer in North India.

Siddiqui Zainab Z Srivastava Anand N AN Sankhwar Satya N SN Zaidi Noorin N Fatima Naseem N Singh Shivangi S Yusuf Mohd M

Therapeutic advances in urology 20190101

<h4>Background</h4>The objective of this study was to evaluate Octamer-binding transcription factor 4 (Oct-4), neutrophil to lymphocyte ratio (NLR) and body mass index (BMI) as independent prognostic biomarkers for prediction of urinary bladder cancer (UBC) outcomes. With the advancement in prognostic biomarker discovery, tumor recurrence is difficult to accurately predict in UBC. UBC is costly to treat due to the requirement of frequent invasive follow-up sessions. Therefore, it is of utmost im ...[more]

PMID: 31632462

Similar Datasets

Project description:It is becoming increasingly clear that no single marker will have the sensitivity and specificity necessary to be used on its own for diagnosis/prognosis of tumors. Interpatient and intratumor heterogeneity provides overwhelming odds against the existence of such an ideal marker. With this in mind, our laboratory has been applying a long term systematic approach to identify multiple biomarkers that can be used for clinical purposes. As a result of these studies, we have identified and reported several candidate biomarker proteins that are deregulated in bladder cancer. Following the conceptual biomarker development phases proposed by the Early Detection Research Network, we have taken some of the most promising candidate proteins into postdiscovery validation studies, and here we report on the characterization of one such biomarker, the bladder cancer-associated protein (BLCAP), formerly termed Bc10. To characterize BLCAP protein expression and cellular localization patterns in benign bladder urothelium and urothelial carcinomas (UCs), we used two independent sets of samples from different patient cohorts: a reference set consisting of 120 bladder specimens (formalin-fixed as well as frozen biopsies) and a validation set consisting of 2,108 retrospectively collected UCs with long term clinical follow-up. We could categorize the UCs examined into four groups based on levels of expression and subcellular localization of BLCAP protein and showed that loss of BLCAP expression is associated with tumor progression. The results indicated that increased expression of this protein confers an adverse patient outcome, suggesting that categorization of staining patterns for this protein may have prognostic value. Finally, we applied a combinatorial two-marker discriminator using BLCAP and adipocyte-type fatty acid-binding protein, another UC biomarker previously reported by us, and found that the combination of the two markers correlated more closely with grade and/or stage of disease than the individual markers. The implications of these results in biomarker discovery are discussed.

Dataset Information

Oct-4: a prognostic biomarker of urinary bladder cancer in North India.

Publications

Oct-4: a prognostic biomarker of urinary bladder cancer in North India.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure